Faron has announced top-line data on dose variation from the phase I/II MATINS study with lead candi...
The Breakthrough Device Designation (BDD) is a timely stepping stone for XVIVO and the Liver Assist ...
Atria is launching a development programme to improve the competitiveness and profitability of its p...
Fantasma Games AB (”Fantasma” eller ”Bolaget”) utvecklar och producerar spel till den globala casino...
Redeye updates its view on Ngenic following the Q2 report.
Stayble Therapeutics är ett forskningsbolag som utvecklar ett läkemedel till patienter med kroniska ...
Redeye gives a short comment on Nanexa’s new project: NEX-22.
Redeye updates its estimates and fair value range to reflect the recent report.
Redeye feels encouraged following today’s positive CHMP opinion on Ximluci (Xlucane), marking a majo...
Redeye comments on Respiratorius after its announcement of the preliminary data from the PK study wi...
Redeye gives a short comment on the Phase III Covid-19 results and reiterate our base case.
Redeye raises its estimates for Energy Save following the strong Q1 2022/23 report and continued sol...
Redeye lowers its valuation of Azelio to SEK6.5 (SEK9) following yesterday’s press release regarding...
Gasprox announced yesterday that it plans to issue a convertible note worth SEK 5.
Signs frame agreement worth EUR 200m… …to build FTTH in Finland A busy start for new CEO, but a lo...
Minskad försäljning inom Health & Wellness Den rapporterade nettoomsättningen för det andra kvartale...
Redeye endorses ISAB’s new IRS contract worth SEK 1.
Redeye sees an opportunity for investors to deepen their understanding of Efecte during its Digitali...
Marimekko elaborated the details of its revised strategy in its CMD and increased its targets to a m...
